Interstitial Lung Disease (ild) Clinical Trials
6 recruiting trials for Interstitial Lung Disease (ild). Eligibility criteria explained in plain English.
TrialFinderData lists 6 Interstitial Lung Disease (ild) clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Across the trials that carry a phase, Phase 2 is the largest group at 50% (1 studies); the largest phase groups are Phase 2: 1, Phase 1: 1.
Research is led by Pulmovant, Inc. (1), University of Bonn (1), University of Dundee (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is inhaled mosliciguat (drug, 1 trial), followed by Dry Powder Inhaler, Single nucleotide polymorphisms (SNP).
Track Interstitial Lung Disease (ild) trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
A Study of Mosliciguat in Combination With Inhaled Treprostinil in PH-ILD
This is a Phase 2, open-label, multi-center clinical study to evaluate the safety and tolerability of inhaled mosliciguat in participants with pulmonary hypertension associated...
AYLo - AutoimmunitY and Loss of y
The AYLo study (AutoimmunitY and Loss of y - Investigating the Role of Hematopoietic Mutations and Mosaic Mutation in the Y Chromosome in Autoimmune Rheumatologic Diseases) aims...
Better Tests- Improving Diagnostic Accuracy and Prognostication in Interstitial Lung Diseases
Patients with interstitial lung diseases (ILD) suffer significant delays in obtaining a diagnosis, and objective evidence of support for immunosuppressive therapies, due to...
Breathlessness Perceptions Within Respiratory Diseases
Breathlessness is a complex symptom that results in poor quality of life, increased hospitalisations and increased mortality. Breathlessness is influenced by physiological,...
A Study of the Pharmacokinetics and Safety of Single-dose Inhaled RJ026 in Healthy Volunteers and Patients With...
This Phase 1 clinical trial investigates the pharmacokinetics and safety profile of single-dose inhaled RJ026 in healthy volunteers and patients with interstitial lung disease...
A Study on the Efficacy and Safety of JAK Inhibitors Versus Calcineurin Inhibitors as Initial Therapy for Interstitial...
This study is a prospective investigation comparing the efficacy and safety of Janus kinase inhibitors versus calcineurin inhibitors as initial therapy for interstitial lung...
Explore Other Conditions
Frequently Asked Questions
There are currently 6 clinical trials for Interstitial Lung Disease (ild), with 6 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Interstitial Lung Disease (ild), review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 0 Phase 3 trials for Interstitial Lung Disease (ild), representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.